Sun Pharmaceutical Medicare Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 23-10-2024
- Paid Up Capital ₹ 2.50 M
as on 23-10-2024
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 8.98%
(FY 2023)
- Profit -134.13%
(FY 2023)
- Ebitda 1.70%
(FY 2023)
- Net Worth -15.00%
(FY 2023)
- Total Assets 58.98%
(FY 2023)
About Sun Pharmaceutical Medicare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Prince Elias, Rakeshchandra Sinha, and Kedar Senapati serve as directors at the Company.
- CIN/LLPIN
U36900GJ2017PLC095132
- Company No.
095132
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2017
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sun Pharmaceutical Medicare?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakeshchandra Sinha  | Director | 19-Apr-2019 | Current |
| Prince Elias | Director | 16-Apr-2024 | Current |
| Kedar Senapati | Director | 27-Feb-2024 | Current |
Financial Performance and Corporate Structure Insights of Sun Pharmaceutical Medicare.
Sun Pharmaceutical Medicare Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.98% increase. The company also saw a substantial fall in profitability, with a 134.13% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sun Pharmaceutical Medicare?
In 2023, Sun Pharmaceutical Medicare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmarack Technologies Private LimitedActive 9 years 2 monthsRakeshchandra Sinha is a mutual person
Caraco Pharmaceuticals Private LimitedActive 12 years 11 monthsPrince Elias and Rakeshchandra Sinha are mutual person
- Neetnav Real Estate Private LimitedActive 14 years 8 months
Prince Elias and Rakeshchandra Sinha are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sun Pharmaceutical Medicare?
Sun Pharmaceutical Medicare has a workforce of 915 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sun Pharmaceutical Medicare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sun Pharmaceutical Medicare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
